Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281443 | 0.89 | IRAK4 (0.38) | IRAK4FLT3DRD4DRD2GRM5 | |
| SCHEMBL4285756 | 0.89 | IRAK4 (0.40) | IRAK4FLT3DRD4DRD2GRM5 | |
| SCHEMBL4288451 | 0.87 | IRAK4 (0.38) | IRAK4FLT3DRD4DRD2GRM5 | |
| SCHEMBL4284557 | 0.86 | KDM4E (0.39) | IRAK4FLT3DRD4DRD2GRM5 | |
| SCHEMBL4287269 | 0.86 | MEN1 (0.41) | IRAK4FLT3DRD4DRD2GRM5 | |
| SCHEMBL4287284 | 0.85 | HPGD (0.42) | CD274 | |
| SCHEMBL4283524 | 0.85 | IRAK4 (0.40) | IRAK4FLT3DRD4DRD2 | |
| SCHEMBL4289532 | 0.85 | IRAK4 (0.41) | IRAK4FLT3DRD4DRD2GRM5 | |
| SCHEMBL4284524 | 0.85 | ALDH1A1 (0.43) | IRAK4FLT3ACKR3 | |
| SCHEMBL4288766 | 0.85 | CD274 (0.42) | CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | IRAK4 415/4885FLT3 1172/4885DRD4 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.